
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte maintains a robust financial outlook due to its strong revenue generation from established products, particularly Jakafi, which is demonstrating solid year-over-year growth of 8% and is anticipated to continue driving revenue as the commercial legacy business remains a crucial asset. The firm's successful launch of Opzelura, showing significant improvements in patients with atopic dermatitis, highlights its potential in dermatology, adding to its diversified pipeline, which includes promising assets like povorcitinib aimed at offsetting future revenue declines from the impending Jakafi patent expiration in 2028. Overall, the combination of steady legacy product performance and advancements in innovative therapies positions Incyte to achieve sustained revenue growth of approximately 5% to 7% moving forward.
Bears say
Incyte's stock faces a negative outlook due to a disappointing pbo-adjusted effect size for its therapies, which fell short of industry benchmarks set by competitive drugs, indicating potential challenges in market differentiation and sales potential. Additionally, concerns over the efficacy and regulatory risks associated with its pipeline products create further uncertainty regarding future revenue growth, particularly as new competitors may emerge. Ultimately, these factors, combined with the company’s history of clinical trial setbacks and potential for dilutive financing, place significant downward pressure on Incyte's financial prospects.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares